PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study

E Gaiffe, T Crepin, J Bamoulid, C Courivaud, M Büchler, E Cassuto, L Albano, J M Chemouny, G Choukroun, M Hazzan, L Kessler, C Legendre, Y Le Meur, N Ouali, A Thierry, A Anota, V Nerich, S Limat, F Bonnetain, D Vernerey, D Ducloux, E Gaiffe, T Crepin, J Bamoulid, C Courivaud, M Büchler, E Cassuto, L Albano, J M Chemouny, G Choukroun, M Hazzan, L Kessler, C Legendre, Y Le Meur, N Ouali, A Thierry, A Anota, V Nerich, S Limat, F Bonnetain, D Vernerey, D Ducloux

Abstract

Background: Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is currently no treatment to prevent or delay the disease. Nevertheless, identification of risk factors make it possible to target a population at risk of developing de novo diabetes. We hypothesized that a short-term treatment with vildagliptin may prevent new onset diabetes after transplantation (NODAT) in high-risk patients.

Methods/design: This is a multicenter, double-blind, placebo-controlled randomized clinical trial. Patients undergoing first kidney transplantation will be included from ten French transplant centers. Included patients will be randomized (1:1) to receive either vildagliptin 100 or 50 mg/day (depending on glomerular filtration rate) during 2 months (the first dose being administered before entering the operating theatres) or placebo. Additional antidiabetic therapy could be administered according to glycemic control. The primary outcome is the proportion of diabetic patients 1 year after transplantation, defined as patients receiving a diabetic treatment, or having a fasting glucose above 7 mmol/l, and/or with an abnormal oral glucose tolerance test. Secondary outcomes include glycated hemoglobin, the occurrence of acute rejection, infection, graft loss and patient death at 3 months, 6 months, and 12 months after transplantation. Outcomes will be correlated to clinical and general characteristics of the patient, cardiovascular history, nephropathy, dialysis history, transplantation data, biological data, health-related quality of life, and the cost-effectiveness of prevention of diabetes with vildagliptin.

Discussion: We have scarce data on the pharmacological prevention of post-transplant diabetes. If our hypothesis is verified, our results will have a direct application in clinical practice and could limit diabetes-associated morbidity, reduce cardiovascular complications, increase quality of life of renal transplant patients, and consequently promote graft and patient survival. Our results may possibly serve for non-transplant patients carrying a high-risk of diabetes associated with other co-morbidities.

Trial registration: ClinicalTrials.gov, NCT02849899 . Registered on 8 February 2016.

Keywords: Diabetes prevention; Kidney transplantation; Randomized controlled trial; Vildagliptin.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
SPIRIT figure of the PRODIG study

References

    1. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178–185. doi: 10.1034/j.1600-6143.2003.00010.x.
    1. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62(4):1440–1446. doi: 10.1111/j.1523-1755.2002.kid582.x.
    1. Ducloux D, Kazory A, Chalopin J-M. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation. 2005;79(4):438–443. doi: 10.1097/01.TP.0000151799.98612.EB.
    1. Chakkera HA, Weil EJ, Swanson CM, Dueck AC, Heilman RL, Reddy KS, et al. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care. 2011;34(10):2141–2145. doi: 10.2337/dc11-0752.
    1. Chakkera HA, Chang Y-H, Ayub A, Gonwa TA, Weil EJ, Knowler WC. Validation of a pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care. 2013;36(10):2881–2886. doi: 10.2337/dc13-0428.
    1. Hecking M, Haidinger M, Döller D, Werzowa J, Tura A, Zhang J, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol JASN. 2012;23(4):739–749. doi: 10.1681/ASN.2011080835.
    1. Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145(6):2653–2659. doi: 10.1210/en.2004-0015.
    1. Rangel EB. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2014;10(11):1585–1605. doi: 10.1517/17425255.2014.964205.
    1. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013;226(2):305–314. doi: 10.1016/j.atherosclerosis.2012.09.012.
    1. Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, et al. IL-6 promoter polymorphism −174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol JASN. 2006;17(8):2333–2340. doi: 10.1681/ASN.2006010066.
    1. Haidinger M, Werzowa J, Hecking M, Antlanger M, Stemer G, Pleiner J, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014;14(1):115–123. doi: 10.1111/ajt.12518.
    1. Werzowa J, Hecking M, Haidinger M, Lechner F, Döller D, Pacini G, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation. 2013;95(3):456–462. doi: 10.1097/TP.0b013e318276a20e.
    1. Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, et al. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res. 2015;24(1):5–18. doi: 10.1007/s11136-013-0583-6.
    1. Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer Oxf Engl. 2010;46(15):2753–2762. doi: 10.1016/j.ejca.2010.07.023.
    1. Haute Autorité de Santé. Choices in methods for economic evaluation a methodological guide. [Internet]. HAS; 2015. .
    1. Courivaud C, Ladrière M, Toupance O, Caillard S, Hurault de Ligny B, Ryckelynck J-P, et al. Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation. Clin Transplant. 2011;25(5):794–799. doi: 10.1111/j.1399-0012.2010.01367.x.
    1. Haute Autorité de Santé. Quelle place pour la sitagliptine dans le diabète de type 2 [Internet]. HAS; 2008. .
    1. Avramovic M, Stefanovic V. Health-related quality of life in different stages of renal failure. Artif Organs. 2012;36(7):581–589. doi: 10.1111/j.1525-1594.2011.01429.x.
    1. Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307. doi: 10.1371/journal.pmed.1001307.
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108. doi: 10.1097/00005650-199711000-00002.
    1. Haines TP, Sinnamon P, Wetzig NG, Lehman M, Walpole E, Pratt T, et al. Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation. Breast Cancer Res Treat. 2010;124(1):163–175. doi: 10.1007/s10549-010-1126-2.
    1. Parkin D, Devlin N. Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ. 2006;15(7):653–664. doi: 10.1002/hec.1086.
    1. Landreneau K, Lee K, Landreneau MD. Quality of life in patients undergoing hemodialysis and renal transplantation--a meta-analytic review. Nephrol Nurs J. 2010;37(1):37–44.
    1. Purnell TS, Auguste P, Crews DC, Lamprea-Montealegre J, Olufade T, Greer R, et al. Comparison of life participation activities among adults treated by hemodialysis, peritoneal dialysis, and kidney transplantation: a systematic review. Am J Kidney Dis. 2013;62(5):953–973. doi: 10.1053/j.ajkd.2013.03.022.
    1. Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabet Med. 2012;29(3):293–302. doi: 10.1111/j.1464-5491.2011.03416.x.
    1. Landman GWD, van Hateren KJJ, Kleefstra N, Groenier KH, Gans ROB, Bilo HJG. Health-related quality of life and mortality in a general and elderly population of patients with type 2 diabetes (ZODIAC-18) Diabetes Care. 2010;33(11):2378–2382. doi: 10.2337/dc10-0979.
    1. Kizilisik AT, Feurer ID, VanBuren DH, Wise P, Van Buren D, Hopkins J, et al. Effects of diabetes and cadaveric organs on functional performance and health-related quality of life after kidney transplantation. Am J Surg. 2003;186(5):535–539. doi: 10.1016/j.amjsurg.2003.07.013.
    1. Gentile S, Jouve E, Dussol B, Moal V, Berland Y, Sambuc R. Development and validation of a French patient-based health-related quality of life instrument in kidney transplant: the ReTransQoL. Health Qual Life Outcomes. 2008;6:78. doi: 10.1186/1477-7525-6-78.
    1. Beauger D, Gentile S, Jouve E, Dussol B, Jacquelinet C, Briançon S. Analysis, evaluation and adaptation of the ReTransQoL: a specific quality of life questionnaire for renal transplant recipients. Health Qual Life Outcomes. 2013;11:148. doi: 10.1186/1477-7525-11-148.
    1. Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013;14(1):57–66. doi: 10.1007/s10198-011-0351-x.
    1. Roborel de Climens A, Tunceli K, Arnould B, Germain N, Iglay K, Norquist J, et al. Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy. Curr Med Res Opin. 2015;31(4):643–665. doi: 10.1185/03007995.2015.1020364.
    1. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3(5):590–598. doi: 10.1034/j.1600-6143.2003.00082.x.
    1. Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int. 2015;28(1):10–21. doi: 10.1111/tri.12413.
    1. ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: 10.1056/NEJMoa0802987.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever